



Protecting human health
and the environment

Protéger la santé
humaine et l'environnement

Re-evaluation Note

REV2026-03

Health Canada's Pesticides Re-evaluation and Special Review Work Plan 2026–2031

(publié aussi en français)

30 June 2026

This document is published by the Health Canada Healthy Environments and Consumer Safety Branch.
For more information, please contact:

Publications

Pesticides Regulatory Directorate
Healthy Environments and Consumer Safety Branch

Health Canada

2 Constellation Drive
8th floor, A.L. 2608 A
Ottawa, Ontario K1A 0K9

Internet:

canada.ca/pesticides
pesticides-info@hc-sc.gc.ca

Information Service:

1-800-267-6315
pesticides.publications@hc-sc.gc.ca



Health
Canada

Santé
Canada

Canada

ISSN: 1925-0630 (print)
1925-0649 (online)

Catalogue number: H113-25/2026-3E (print version)
H113-25/2026-3E-PDF (PDF version)

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2026

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.

Table of contents

Background		1
Work plan development		2
Part A	Special reviews	3
	Part A, Table 1	Publication target dates for proposed and final special review decisions planned between 1 April 2026 to 31 March 2027 (in chronological order)
		3
	Part A, Table 2	Additional Special reviews currently under the review phase
		5
Part B	Re-evaluations and standalone quantitative cumulative health risk assessment	8
	Part B, Table 1	Publication target dates for proposed and final re-evaluation decisions, and cumulative health risk assessments planned between 1 April 2026 to 31 March 2027 (in chronological order)
		8
	Part B, Table 2	Additional Re-evaluations and Cumulative Health Risk assessments currently under the review phase
		9
Part C	Re-evaluations – Early stage of re-evaluation process	11
	Part C, Table 1	List of actives (in alphabetical order) for which the scoping reviews are targeted first
		11
	Part C, Table 2	List of actives (in alphabetical order) in the early part of the re-evaluation process
		12
Part D	Re-evaluation initiations between 1 April 2026 and 31 March 2031	16
	Part D, Table 1	Re-evaluation initiations between 1 April 2026 and 31 March 2027 (based on initiation date)
		16
	Part D, Table 2	Future re-evaluation initiations between 1 April 2027 and 31 March 2031
		17

Background

The purpose of this document is to inform registrants, pesticide regulatory officials and the Canadian public of the re-evaluation and special review work (in other words, the post-market reviews) planned by Health Canada for the next five fiscal years from 1 April 2026 to 31 March 2031. This document presents updates to the information last published in Re-evaluation Note REV2025-01, *Pest Management Regulatory Agency Re-evaluation and Special Review Work Plan 2025–2030*.

Health Canada regulates pesticides in Canada, with the primary objective of protecting the health of Canadians and the environment. A pesticide product may only be sold or used in Canada if it has been registered or otherwise authorized under the authority of the *Pest Control Products Act*. Health Canada uses a rigorous science-based risk assessment approach to ensure that the product meets health and environmental protection standards and has value.

As part of the post-market program, registered pesticides are re-evaluated on a cyclical basis to determine their continued acceptability. Pesticides may also be re-evaluated as a result of changes in the information required or the procedures used by Health Canada to determine that the pesticide meets current health, environment and value standards. The re-evaluation process is described in Regulatory Directive DIR2016-04, *Management of Pesticides Re-evaluation Policy*. In addition, a special review may be initiated at any time to address the identified aspect(s) of concern, and a special review is triggered only under certain circumstances. Special reviews differ from re-evaluations in that a special review is intended to examine only specific aspects of a pesticide. Additional information on special reviews can be found in the PMRA Guidance Document, *Approach to Special Reviews of Pesticides*.

As required under the *Pest Control Products Act*, Health Canada publishes all post-market proposed decisions for public consultation. Following consultation, comments and information submitted by the public and other stakeholders are considered before Health Canada issues a final decision. Stakeholders are encouraged to stay informed of upcoming consultations and decisions for pesticides by visiting the Pesticides and pest management section of [Canada.ca](https://www.canada.ca).

This work plan includes the target dates for the proposed and final decisions to be published in the current fiscal year, and the status of all open re-evaluations and special reviews. In addition, new re-evaluations expected to be initiated from 1 April 2026 to 31 March 2031 are included for improved transparency for registrants and stakeholders.

Bill C-31 (A second Act to implement certain provisions of the budget tabled in Parliament on 4 November 2025), includes proposed amendments to the *Pest Control Products Act* to remove the cyclical pesticide re-evaluation requirement to enable modern, risk-based oversight. The impacts of this proposed change on re-evaluation planning will be reflected in an updated public work plan should the proposed amendments become law.

In addition, this five-year work plan may change in response to workload and emerging issues that require priority action. During the course of the year, interested stakeholders can monitor Health Canada's Public Registry to view the announcement of new re-evaluations and special reviews, as well as other documents relevant to specific post-market reviews.

Work plan development

The re-evaluation and special reviews of several actives included in last year's plan (REV2025-01) have been carried over to this fiscal year due to the complex nature of the re-evaluations and the need to review large volumes of data and extensive use patterns. Resources were also focused on other priorities including an increased number of pre-market notices of objection and special review initiations. The number of re-evaluation initiations required as per the 15-year legislative requirement continues to be high.

Health Canada's Continuous Oversight Model and Proportional Effort Framework support operations and render them more efficient to ensure that the Health Canada responds to emerging risks in a more timely manner and that the limited scientific resources are focused on issues that matter most. Health Canada published and implemented the Policy on continuous oversight of pesticides and the Policy on proportional effort in 2025. Implementation of the proportional effort (PE) policy enables Health Canada to better focus review efforts to increase overall protection and make progress to reduce the re-evaluation backlog. The PE categorization informs the scope and level of effort needed for a review, and it guides Health Canada in identifying key areas of focus for re-evaluation. Active ingredients will continue to be reviewed according to Health Canada's policies, such as the existing Management of Pesticide Re-evaluation Policy, which outline timelines, data requirements and assessments.

The following tables outline the target publication dates for the proposed and final decisions of special reviews and re-evaluations established. In addition, next milestone target dates for the three standalone quantitative cumulative health risk assessments initiated are also included. Considering the ongoing comprehensive expenditure review within Health Canada, this work plan only includes publication dates of proposed and final decisions in the current fiscal year (between 1 April 2026 to 31 March 2027). The revised publication targets for proposed and final decisions in subsequent years will be included in the next updated workplan.

Part A Special reviews

Special reviews are very focused and examine only specific aspects of a pesticide as outlined in PMRA Guidance Document, *Approach to Special Reviews of Pesticides*. While the aspect of concerns for each special review is included in the special review announcement available in the Public Registry, they are captured in the table below for easy access.

Part A, Table 1 Publication target dates for proposed and final special review decisions planned between 1 April 2026 to 31 March 2027 (in chronological order)

Active ingredient name	Aspect of concerns	Target date
Proposed special review decision (PSRD) – For consultation		
MCPA • MCPA (present as acid) • MCPA (present as amine salts: diethanolamine, dimethylamine, or mixed amines) • MCPA (present as esters) • MCPA (present as potassium salt or as sodium salt)	Human health: Potential inhalation occupational (mixing/loading/applying) and residential risk from the use of MCPA.	May 2026
Ethalfuralin	Human health: Potential cancer risks from occupational exposure to ethalfuralin for: • operators who are mixing and loading granular fertilizers with ethalfuralin products in commercial blending facilities; and • custom applicators (in field) of the liquid-fertilizer blends.	August 2026
Hydantoins • Available chlorine present as 1-bromo-3-chloro-5,5-dimethylhydantoin and related hydantoins • Available bromine present as 1-bromo-3-chloro-5,5-dimethylhydantoin and related hydantoins • Available chlorine present as 1-bromo-3-chloro-5,5-dimethylhydantoin, 1,3-dichloro-5,5-dimethylhydantoin, 1,3-	Human health: Potential occupational inhalation risk for workers handling halohydantoin products formulated as granules. Potential residential postapplication cancer risk from incidental oral exposure to bromate in outdoor swimming pools treated with bromine-based halohydantoins and in swimming pools, spas and hot tubs in combination with	August 2026

Active ingredient name	Aspect of concerns	Target date
dichloro-5-ethyl-5-methylhydantoin and related hydantoins Available Chlorine Present as 1,3-Dichloro-5,5-Dimethylhydantoin and 1,3-Dichloro-5-Ethyl-5-Methylhydantoin	electrolysis, ozonation or UV devices.	
Novaluron (preliminary risk assessment) Note: Health Canada will be publishing a preliminary risk assessment* in the Public Registry prior to the publication of the proposed special review decision.	Human health: Potential dietary risks (food and water) from exposure to novaluron	June 2026
Atrazine Note: Health Canada will be re-consulting on the environmental review part.	Human health and environment: Potential changes to toxicology endpoint(s) used for previous human health and environmental risk assessments. The impact of those potential changes to human health from atrazine in drinking water. The impact of those potential changes to the environment from atrazine in surface water.	January 2027

Active ingredient name	Aspect of concerns	Target date
Final special review decision (SRD)		
Chlorothalonil	Human health: - Potential exposure to metabolites R417888, R419492, R471811, SYN507900, M3, M11, M2, M7 and M10 from groundwater. - Potential carcinogenicity of chlorothalonil (related to dietary exposure). - Potential genotoxicity of chlorothalonil metabolites. Environment: - Potential changes to environmental fate and ecotoxicological endpoints (including parent and transformation products). - Potential risk to amphibians and fish.	February 2027

* The purpose of a preliminary risk assessment is to obtain specific information prior to proceeding with the development of the risk management proposal.

Part A, Table 2 Additional special reviews currently under the review phase

Health Canada published target publication dates for most of the actives in the following table in REV2025-01. Timelines for the proposed and final decisions of these actives are being re-visited to reflect the government's comprehensive expenditure review outcome and resource availability, and the target dates will be communicated in the next 5-year workplan.

Active ingredient name	Aspect of concerns
Proposed special review decision (PSRD) – For consultation	
Chlorpropham	Human health: Dietary (food only) risk from exposure to chlorpropham and 3-chloroaniline residues.

Active ingredient name	Aspect of concerns
Dimethomorph	Human health: Potential reproductive and developmental toxicity, including potential endocrine related effects. Environment: Potential reproductive risk to wild mammals.
Ethofumesate	Human health: Potential risk from exposure to ethofumesate and transformation products NC 8493, NC 9607, and NC 20645 in drinking water; and Environment: Potential risk to terrestrial and aquatic plants.
Glufosinate ammonium	Human health: Potential reproductive toxicity (including developmental toxicity); Potential occupational health risk; and Potential bystander risk.
Propiconazole	Human health: Potential exposure to propiconazole's transformation products (NOA436613, SYN547889, and CGA91305) in groundwater (drinking water). Environment: Potential reproductive risk to fish.
Thiacloprid	Human health: Potential exposure to thiacloprid's transformation products M30, M34, and M46 in groundwater (drinking water)

Active ingredient name	Aspect of concerns
Final special review decision (SRD)	
Iodocarb (3-iodo-2-propynyl butyl carbamate)	Human health: Potential dermal and inhalation risks of concern for secondary workers (machinists) exposed to iodocarb-treated metalworking fluids (MWF). Potential dermal and inhalation risks of concern for mixers/loaders treating MWF with iodocarb.
Dicamba • Dicamba (present as acid, ester, salts) • Dicamba (present as n,n-bis(3-aminopropyl)methylamine salt) • Dicamba (present as monoethanolamine salt) • Dicamba (present as n-(2-aminoethyl)-1,2-ethanediamine salt) • Dicamba (present as acid) • Dicamba (present as potassium salt) • Dicamba (present as sodium salt) • Dicamba (present as dimethylamine salt) • Dicamba (present as diglycolamine salt) • Dicamba (present as isopropylamine salt) • Dicamba (present as diethanolamine salt)	Environment: Risk to non-target terrestrial plants from the use of dicamba products (Over-the-Top and non-Over-the-Top uses).

Part B Re-evaluations and standalone quantitative cumulative health risk assessment

Based on the currently available resources, Health Canada has established target publication dates for the proposed and final decisions of the re-evaluations, as well as the next milestone target dates for the three standalone quantitative cumulative health risk assessments.

Part B, Table 1 Publication target dates for proposed and final re-evaluation decisions, and cumulative health risk assessments planned between 1 April 2026 to 31 March 2027 (in chronological order)

Active ingredient name	Re-evaluation category ¹	Target date
Proposed re-evaluation decisions (PRVD) – For consultation		
Ammonium bromide	3	June 2026
Mecoprop cluster: - Mecoprop-P (present as Acid) - Mecoprop-P (present as Dimethylamine Salt) - Mecoprop-P (present as Potassium Salt)	1	September 2026
Fenamidone	1	September 2026
Coniothyrium minitans Strain Con/M/91-08	3	October 2026
Ozone	3	October 2026
Sulfuryl fluoride	3	October 2026
Fluvalinate-Tau	3	November 2026
<i>Beauveria bassiana</i> Strain Hf23	3	December 2026
Bispyribac-Sodium	3	December 2026
Pyroxsulam	3	December 2026
2-(Hydroxymethyl)-2-Nitro-1,3-Propanediol	3	January 2027
N-Decanol N-Octanol	3	February 2027
Naphthalene Acetic Acid (present as Ethyl Ester, Sodium Salt, or as Ammonium Salt)	3	February 2027
Cyprodinil	1	February 2027
Tetrakis(hydroxymethyl) Phosphonium Sulphate	3	February 2027
Clothianidin general re-evaluation	1	March 2027
Gibberellins cluster: - Gibberellic acid - Gibberellins A4A7	2	March 2027

Active ingredient name	Re-evaluation category ¹	Target date
Rodenticide Cluster: • Brodifacoum • Bromadiolone • Bromethalin • Chlorophacinone • Diphacinone (present in free form or as sodium salt) • Warfarin (present in free form or as sodium salt) • Zinc phosphide • Difethialone	1	March 2027
Spinetoram	1	March 2027
Spinosad	1	March 2027
Thiamethoxam general re-evaluation	1	March 2027
Cumulative risk assessment		
Cumulative Health Risk Assessment: Triazole – project plan ²	1	June 2026
Final re-evaluation decision (RVD)		
Sulphur	2	April 2026
Ferric Sodium Ethylenediaminetetraacetic Acid	3	April 2026
Iodosulfuron-methyl-sodium	3	July 2026
Potassium bicarbonate	2	August 2026
DEET plus related active toluamides	1	October 2026
Prohexadione calcium	3	October 2026
Silicon dioxide cluster: • Silica aerogel • Silicon dioxide	3	November 2026

- 1 Re-evaluation category outlined takes into consideration of proportional effort approach outlined in the PE policy
- 2 A separate project plan will be published as per process described in Science Policy Note SPN2018-02, *Cumulative Health Risk Assessment Framework*.

Part B, Table 2 Additional Re-evaluations and Cumulative Health Risk assessments currently under the review phase

Timelines for the proposed and final decisions of these actives are being updated and the target dates will be communicated in the next 5-year workplan.

Active ingredient name	Re-evaluation category ¹
Proposed re-evaluation decision (PRVD)	
10,10'-Oxybis(Phenoxarsine)	3
Cyazofamid	3
Nonylphenoxypolyethoxyethanol	3
Glufosinate ammonium	1

Active ingredient name	Re-evaluation category ¹
Boscalid	2
D-cis, trans-allethrin	1
Ethofumesate	1
(S)-Methoprene	2
Acetamiprid	1
Fluazinam	1
Thiacloprid	1
Methoxyfenozide	1
Metribuzin	1
Naled	1
Phorate	1
Picolinafen	1
Prothioconazole	1
6-Benzylaminopurine	1
Bensulide	1
Tetrachlorvinphos	1
2-(Thiocyanomethylthio)Benzothiazole	2
Aminopyralid - Aminopyralid - Aminopyralid Triisopropanolamine Salt - Aminopyralid Potassium Salt	3
Antimicrobial cluster 1,2-Benzisothiazolin-3-One 2-Methyl-4-Isothiazolin-3-One 4,5-Dichloro-2-N-Octyl-3(2H)-Isothiazolone 5-Chloro-2-methyl-4-isothiazolin-3-One	2
<i>Beauveria bassiana</i> Strain GHA	3
<i>Clonostachys rosea</i> Strain J1446	2
Cyprosulfamide	2
<i>Metarhizium brunneum</i> Strain F52	2
Mineral Oil	2
Methylene Bis(Thiocyanate)	2
Pyrimethanil	2
Final re-evaluation decision (RVD)	
S-metolachlor and R-enantiomer	1
Azoxystrobin	1
Famoxadone (Consultation started on 31 March 2026)	1
Cumulative risk assessment	
Cumulative Health Risk Assessment: N-Methyl Carbamates – Consultation for a proposed decision	1
Cumulative Health Risk Assessment: Organophosphates – Consultation for a proposed decision	1

¹ Re-evaluation category outlined takes into consideration of proportional effort approach outlined in the PE policy.

Part C Re-evaluations – Early stage of re-evaluation process

The re-evaluations of the following active ingredients are in the early stage of the re-evaluation process. Health Canada will focus on the scoping reviews of these actives to determine the re-evaluation categories. Table 1 is the list of actives targeted first. The outcome of the scoping reviews will further inform prioritization of active ingredients for review phase, and the expected timelines for their public consultation will be included in a future update.

Part C, Table 1 List of actives (in alphabetical order) for which the scoping reviews are targeted first

Active ingredient name
2-Phenylphenol and Salts cluster: 2-Phenylphenol 2-Phenylphenol (present as potassium salt) 2-Phenylphenol (present as sodium salt)
2,4-D cluster: 2,4-D (present as Acid) 2,4-D (present as Amine Salts: Dimethylamine Salt, Diethanolamine Salt, or Other Amine Salts) 2,4-D (present as choline salt) 2,4-D (present as Low Volatile Esters)
<i>Bacillus thuringiensis</i> ssp. Tenebrionis
<i>Bacillus thuringiensis</i> subspecies kurstaki (all strains)
<i>Bacillus thuringiensis</i> , Serotype H-14
Bromoxynil
Didecyl Dimethyl Ammonium Chloride Cluster (DDAC): - Didecyl Dimethyl Ammonium Chloride – other - Didecyldimethylammonium (present as carbonate and bicarbonate salts) - Dioctyl Dimethyl Ammonium Chloride (present as carbonate and bicarbonate salts) - Octyl Decyl Dimethyl Ammonium Chloride - Oxydiethylene Bis(Alkyl Dimethyl Ammonium Chloride)
Diphenylamine
Ipconazole
Lime Sulphur or Calcium Polysulphide
Maleic Hydrazide
Napropamide
Oxamyl
Oxirane Derivatives - 50% Minimum
Oxyfluorfen
Rotenone
Streptomycin
Thiencarbazone-Methyl
<i>Verticillium albo-atrum</i> , Isolate Wcs850

Part C, Table 2 List of actives (in alphabetical order) in the early part of the re-evaluation process

Based on available resources, scoping reviews of actives in Table 2 will be targeted following the completion of the actives in Table 1 above, and Health Canada will provide an updated status of the following actives in the work plan to be published in spring 2027.

Active ingredient name
1,2-Dibromo-2,4-Dicyanobutane
Acequinocyl
Acifluorfen, present as Sodium Salt
Alkyl Dimethyl Benzyl Ammonium Chloride Cluster (ADBAC):
• N-Alkyl (40% C12, 50% C14, 10% C16) Dimethyl Benzyl Ammonium Chloride • N-Alkyl (68% C12, 32% C14) Dimethyl Ethylbenzyl Ammonium Chloride • N-Alkyl (5% C12, 60% C14, 30% C16, 5% C18) Dimethyl Benzyl Ammonium Chloride • N-Alkyl (67% C12, 25% C14, 7% C16, 1% C18) Dimethyl Benzyl Ammonium Chloride • Diisobutylphenoxyethoxyethyl Dimethyl Benzyl Ammonium Chloride • N-Alkyl (40% C12, 50% C14, 10% C16) Dimethyl Benzyl Ammonium Saccharinate • N-Alkyl(25% C12, 60% C14, 15% C16)Dimethylbenzylammonium Chloride • N-Dialkyl(5% C12, 60% C14, 30% C16, 5% C18)Methylbenzylammonium Chloride
Alkyl trimethylenediamines cluster:
• N-Coco-Alkyltrimethylene Diamines present as Monobenzoate Salt • Alkyl-1,3-Propylene Diamine Acetates • 1-Alkylamino-3-Aminopropane (Alkyl Groups As Derived From Coconut Oil Fatty Acids)
Antimicrobials cluster:
• 2,2-Dibromo-3-Nitrilopropionamide • Bronopol
Atrazine (plus related active Triazines)
Bentazon cluster:
• Bentazon (present as Sodium Salt) • Bentazone
Bifenazate
Bromacil (present in free form, as dimethylamine salt, or as lithium salt)
Carbathiin
Carbendazim
Carfentrazone-Ethyl
Chlormequat Chloride
Chlorpropham
Chlorantraniliprole
Clomazone
Cloransulam-Methyl
Daminozide

Active ingredient name
Dicamba cluster: - Dicamba (present as acid) - Dicamba (present as acid, ester, salts) - Dicamba (present as diethanolamine salt) - Dicamba (present as diglycoamine salt) - Dicamba (present as dimethylamine salt) - Dicamba (present as isopropylamine salt) - Dicamba (present as monoethanolamine salt) - Dicamba (present as N-(2-Aminoethyl)-1,2-Ethanediamine Salt) - Dicamba (present as N,N-Bis(3-Aminopropyl)Methylamine Salt) - Dicamba (present as potassium salt) - Dicamba (present as sodium salt)
Dichlobenil
Diiflubenzuron
Dimethenamid-P
Diuron
Dioxaborinanes cluster: 2,2-(1-Methyltrimethylenedioxy)Bis-(4-Methyl-1,3,2-Dioxaborinane) 2,2-Oxybis(4,4,6-Trimethyl-1,3,2-Dioxaborinane)
Dithiopyr
Dodine
Endothal cluster: - Endothal - Endothal, present as N,N-Dimethylalkylamine salt
EPTC (S-ethyl N,N-dipropylcarbamothioate)
Etridiazole
Fenbutatin Oxide
Fish toxicants cluster: 4-Nitro-3-(trifluoromethyl) phenol sodium salt - Niclosamide
Flumioxazin
Formetanate Hydrochloride
Glutaraldehyde
Hexazinone
Imazapyr
Mandipropamid
MCPA cluster: - MCPA (present as Acid) - MCPA (present as Amine Salts: Diethanolamine, Dimethylamine, or Mixed Amines) - MCPA (present as Esters) - MCPA (present as Potassium Salt or as Sodium Salt)
Mesotrione
Metalaxyl cluster: - Metalaxyl - Metalaxyl-M and S-Isomer

Active ingredient name
Metaldehyde
Novaluron
Pendimethalin
Phenmedipham
Phosphonic acid cluster: • Mono- and Di-Potassium Salt of Phosphorous Acid • Mono- and Di-basic Sodium, Potassium, and Ammonium Phosphites
Picloram cluster: • Picloram (present as potassium salt) • Picloram (present as acid) • Picloram (present as amine salts)
Pinoxaden
Prometryne Plus Related Active Triazines
Propyzamide
Pyraclostrobin
Pyrasulfotole
Saflufenacil
Simazine Plus Related Active Triazines
Sodium Chlorite and Sodium Chlorate cluster (industrial uses): • Sodium Chlorite • Sodium Chlorate
Spirodiclofen
Spiromesifen
Spirotetramat
Sulfentrazone
Sulfonyl Ureas cluster: • Chlorsulfuron • Ethametsulfuron-Methyl • Metsulfuron-Methyl • Nicosulfuron • Rimsulfuron • Thifensulfuron-Methyl
Terbacil
Topramezone
Triallate
Triazinetrione cluster: • Available Chlorine, present as Sodium Dichloro-S-Triazinetrione • Available Chlorine, present as Trichloro-S-Triazinetrione • Trichloro-S-Triazinetrione • Available Chlorine present as Trichloro-S-Triazinetrione and Sodium Dichloro-S-Triazinetrione

Active ingredient name
Tribenuron-Methyl
Triclopyr (present as butoxyethyl ester)
Trifloxystrobin
Trifluralin

Part D Re-evaluation initiations between 1 April 2026 and 31 March 2031

Under the *Pest Control Products Act*, Health Canada is mandated to initiate re-evaluations for each registered pesticide on a 15-year cycle, based on the most recent major decision affecting the registration, including its initial registration (subsection 16(2) of the *Pest Control Products Act*). On a yearly basis, Health Canada updates the list of re-evaluations to be initiated in the next five fiscal years.

Bill C-31 (A second Act to implement certain provisions of the budget tabled in Parliament on 4 November 2025), includes proposed amendments to the *Pest Control Products Act* to remove the cyclical pesticide re-evaluation requirement to enable modern, risk-based oversight. The proposed changes will impact the prospective long-term re-evaluation initiations should the proposed amendments become law. Any changes will be reflected in an updated public work plan.

Part D, Table 1 Re-evaluation initiations between 1 April 2026 and 31 March 2027 (based on initiation date)

To further improve transparency for stakeholders and registrants, specific month of initiation of re-evaluation is included.

Active ingredient name	Initiation dates
1 April 2026 – 31 March 2027	
Diquat	April 2026
Iron (present as FeHEDTA)	April 2026
Tembotrione	April 2026
Animal repellent cluster: • Castor Oil • Dried Eggs • Fish Meal Mixture • Fish Oil Mixture • Meat Meal Mixture • Wintergreen Oil • Garlic Oil	May 2026
<i>Pseudomonas syringae</i> – Strain Esc-10	July 2026
<i>Lactobacillus casei</i> Strain LPT-111	July 2026
<i>Lactobacillus rhamnosus</i> Strain LPT-21	
<i>Lactococcus lactis</i> ssp. <i>cremoris</i> Strain M11/CSL	
<i>Lactococcus lactis</i> ssp. <i>lactis</i> Strain L164/CSL	
<i>Lactococcus lactis</i> ssp. <i>lactis</i> Strain L1102/CSL	
Lactic Acid	
Citric Acid	August 2026
Mesosulfuron-Methyl	
Metrafenone	
Paradichlorobenzene	
Tefluthrin	September 2026

Active ingredient name	Initiation dates
Thymol	October 2026
Imazethapyr	October 2026
Trimethoxysilyl quats cluster: 3-(Trihydroxysilyl)-Propyldimethyloctadecyl Ammonium Chloride (trimethoxysilyl quats) 3-(Trimethoxysilyl)-Propyldimethyloctadecyl Ammonium Chloride (trihydroxysilyl quats)	October 2026
Diodofon	October 2026
Hexahydro-1,3,5-Tris(2-Hydroxyethyl)-S-Triazine	October 2026
Oxalic Acid Dihydrate	November 2026
D-Limonene	November 2026
Flonicamid	December 2026
Saponins Of <i>Chenopodium Quinoa</i>	December 2026
1,4-Dimethylnaphthalene	January 2027
Tralkoxydim	January 2027
Iodocarb – Other	March 2027
Thiabendazole	March 2027

Part D, Table 2 Future re-evaluation initiations between 1 April 2027 and 31 March 2031

The initiations for the active ingredients in the following table will be updated annually.

1 April 2027 to 31 March 2028
Heavy duty wood preservative cluster: - Arsenic Acid - Chromic Acid - Creosote - Zinc (present as Zinc Oxide) - Copper (present as Basic Copper Carbonate)
Hydantoins cluster: - Available Bromine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin and Related Hydantoins - Available Chlorine present as 1,3-Dichloro-5,5-Dimethylhydantoin and 1,3-Dichloro-5-Ethyl-5-Methylhydantoin - Available Chlorine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin and Related Hydantoins - Available Chlorine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin, 1,3-Dichloro-5,5-Dimethylhydantoin, 1,3-Dichloro-5-Ethyl-5-Methylhydantoin and Related Hydantoins
<i>Bacillus firmus</i> I-1582
Clopyralid
Copper (present as Copper 8-Quinolinolate)
Copper (present as Copper Naphthenate)
Zinc as Elemental (present as Zinc Naphthenate)
<i>Cydia pomonella granulovirus</i> (Strain M)

Extract of <i>Reynoutria sachalinensis</i>
Fluopicolide
Formaldehyde
Paraformaldehyde
Icaridin
Indaziflam
Metofluthrin
Oriental Mustard Seed Meal
<i>Paecilomyces fumosoroseus</i> Strain FE 9901
Penflufen
Penthiopyrad
<i>Phoma macrostoma</i>
Propiconazole
<i>Trichoderma asperellum</i> Strain T34
1 April 2028 to 31 March 2029
Ametoctradin
Ammonia (present as Ammonium Sulfate)
<i>Aureobasidium pullulans</i> cluster: • <i>Aureobasidium pullulans</i> Strain DSM 14940 and DSM 14941 • <i>Aureobasidium pullulans</i> Strain DSM 14940 • <i>Aureobasidium pullulans</i> Strain DSM 14941
<i>Bacillus subtilis</i> var. <i>amyloliquefaciens</i> Strain FZB24
<i>Clavibacter michiganensis</i> spp. <i>michiganensis</i> Bacteriophage
Cloquintocet-Mexyl
Denatonium Benzoate
Ethalfluralin
Fenoxaprop-P-Ethyl
Fluazifop-P-Butyl and S-Isomer
Fluopyram
Fluoxastrobin
Fluxapyroxad
Kasugamycin (Present as Hydrochloride Hydrate)
Malathion
MCPB (Present as Sodium Salt)
Mint oil cluster: • Cornmint Oil • Methyl Salicylate
Octadecadien-1-ol cluster: • (E,Z)-2,13-Octadecadien-1-yl Acetate • (Z,Z)-3,13-Octadecadien-1-ol • (E,Z)-3,13-Octadecadien-1-ol
Picoxystrobin
Poly[Oxyethylene(Dimethyliminio)Ethylene (Dimethyliminio)Ethylene Dichloride]
Potassium Dimethyldithiocarbamate Salts
<i>Pseudomonas fluorescens</i> Strain CL145A
Pyroxasulfone

Sedaxane
Sulfoxaflor
Tetraconazole
<i>Trichoderma virens</i> Strain G-41
1 April 2029 to 31 March 2030
3-Decen-2-One
<i>Bacillus subtilis</i> Strain GB03
Chlorfenapyr
Cyantraniliprole
Ethylene Oxide
Garlic Juice
Garlic Powder
Halosulfuron (Present as Methyl Ester)
Myclobutanil
P-Menthane-3,8-Diol And Related Oil Of Lemon Eucalyptus Compounds
Tea Tree Oil
Tributyl Tetradecyl Phosphonium Chloride
1 April 2030 to 31 March 2031
3-chloro-4-methylaniline hydrochloride
3-Methyl-4-chlorophenol (or: p-chloro-m-cresol) and 4-Chloro-3-methylphenol (sodium salt)
Aminocyclopyrachlor
<i>Bacillus thuringiensis</i> SSP. <i>aizawai</i> strain ABTS-1857
Clofentezine
Cyflumetofen
Ethaboxam
Flumetsulam
Flutriafol
Halauxifen (Present as methyl ester)
Isofetamid
Isoxaben
<i>Lymantria dispar</i> multicapsid nucleopolyhedrovirus strain LDP-67
Paclobutrazol
<i>Phlebiopsis gigantea</i>
Propoxur
Pyraflufen-ethyl
<i>Trichoderma harzianum</i> rifai strain T-22

Note: The following actives included in the REV2025-01 for initiation in the fiscal year of 2026–2027 will not be initiated:

- Dichlorprop-P, Dichlorprop-P (Present As Dimethylamine Salt), and Naphtalene, will not be initiated as these products were discontinued.

Note: The following active included in the REV2025-01 for initiation in the fiscal year 2029–2030 will not be initiated:

- *Streptomyces acidiscabies* Strain R1-110t Cells and Spent Fermentation Media will not be initiated as all of associated products were discontinued.